Article Sidebar

PDF
Date Published: 28/06/2025
Online Published: 14/05/2025
Abstract Views: 3
Views PDF: 3
DOI: https://doi.org/10.56283/1859-0381/892
Issue
Vol. 21 No. 3 (2025)
Section
ORIGINAL RESEARCH
How to Cite
1.
DOAN TTL, DAO GB, LUU TTN, et al. COMPREHENSIVE IN VITRO ASSESSMENT OF THE SAFETY PROFILE OF Bacillus subtilis Eramic 25 AND ITS POTENTIAL FOR APPLICATION IN THE DEVELOPMENT OF FUNCTIONAL FOODS AND HEALTH SUPPLEMENTS. Tạp chí Dinh dưỡng và Thực phẩm. 2025;21(3):1-12. doi:10.56283/1859-0381/892

COMPREHENSIVE  IN VITRO ASSESSMENT OF THE SAFETY PROFILE OF Bacillus subtilis Eramic 25 AND ITS POTENTIAL FOR APPLICATION IN THE DEVELOPMENT OF FUNCTIONAL FOODS AND HEALTH SUPPLEMENTS

Thi Thuy Linh DOAN1, Gia Bach DAO2, Thi Thuy Ngan LUU1, Ba Binh NGO1, Thi Thanh Hoa HOANG2, Vu Trung NGUYEN3, Thi Hoi LE2,
1 Eramic Technology Era Joint Stock Company, Vietnam
2 Hanoi Medical University, Vietnam
3 Pasteur Institute in Ho Chi Minh City

Main Article Content

Abstract

Aims: This study aimed to comprehensively assess the in vitro safety profile of Bacillus subtilis Eramic 25 in accordance with the guidelines of GRAS, the United States Food and Drug Administration (FDA), and the European Food Safety Authority (EFSA), through the evaluation of antimicrobial activity, cytotoxicity, and the presence of antibiotic resistance and virulence genes associated with safety.

Methods: The conducted assays included the evaluation of antibacterial activity against pathogenic bacteria, cytotoxicity testing on two cell lines, Vero and HT-29, as well as genomic analysis to identify the presence of virulence genes and antibiotic resistance genes

Results: The B. subtilis Eramic 25 strain does not inhibit selected common pathogens, and exhibits no cytotoxic effects on Vero and HT-29 cell lines. Furthermore, genomic analysis confirmed that this strain does not genes encoding for toxins and hemolytic genes. Antibiotic resistance genes are not located on plasmids or transposable elements, indicating a very low risk of horizontal gene transfer of antibiotic resistance.

Conclusion: B. subtilis Eramic 25 meets the in vitro safety criteria recommended by GRAS, FDA, and EFSA. These findings support the potential application of this strain in the production of probiotics, functional foods, and food products for human consumption, and provide a basis for animal studies and clinical trials on human.

Keywords

𝐵𝑎𝑐𝑖𝑙𝑙𝑢𝑠 𝑠𝑢𝑏𝑡𝑖𝑙𝑖𝑠, cytotoxin, toxin genes, antibiotic resistance genes

Article Details

References

1. Tamang JP, Watanabe K, Holzapfel WH. Diversity of microorganisms in global fermented foods and beverages. Front Microbiol. 2016;7:377.
2. European Food Safety Authority (EFSA); Ricci A, Allende A, Bolton D, et al. Scientific opinion on the update of the list of qualified presumption of safety (QPS) recommended microbiological agents intentionally added to food or feed as notified to EFSA. EFSA Journal. 2023;21(1):7784.
3. U.S. Food and Drug Administration. Substances generally recognized as safe. 21 CFR §170 Subpart E. Revised 2023. Accessed April 28, 2025.
4. GRAS Associates. GRAS Notice No. 1143: Bacillus subtilis NRRL 68053. U.S. Food and Drug Administration. Published 2023. Accessed April 28, 2025.
5. European Food Safety Authority (EFSA). Guidance on the assessment of bacterial susceptibility to antimicrobials of human and veterinary importance. EFSA Journal. 2012;10(6):2740.
6. European Food Safety Authority (EFSA). Guidance on the assessment of the toxigenic potential of Bacillus species used in animal nutrition. EFSA Journal. 2014;12(5):3665.
7. Đào Gia Bách, Đoàn Thị Thuỳ Linh, Lưu Thị Thuỷ Ngân, Lê Thị Hội. Phân lập, tuyển chọn và đánh giá đặc tính các chủng Bacillus tiềm năng ứng dụng cho chế phẩm probiotic. Vietnam Journal of Science and Technology, Section B. 2024;66(5):29-33.
8. GRAS Associates. GRN No. 956 Bacillus subtilis ATCC SD-7280. US Food and Drug Administration website. Published 2021. Accessed December 23, 2024.
9. Ramachandran R, Chalasani AG, Lal R, et al. A broad-spectrum antimicrobial activity of Bacillus subtilis RLID 12.1. Scientific World Journal. 2014;2014:968487.
10. Williams N, Weir TL. Spore-based probiotic Bacillus subtilis: Current applications in humans and future perspectives. Fermentation. 2024;10(2):78.
11. Hong HA, Duc LH, Cutting SM. The use of bacterial spore formers as probiotics. FEMS Microbiology Reviews. 2005;29(4):813–835.
12. Urdaci MC, Bressollier P, Pinchuk I. Bacillus clausii probiotic strains: antimicrobial and immunomodulatory activities. J Clin Gastroenterol. 2004;38(6 Suppl):S86-S90.
13. Lee NK, Kim WS, Paik HD. Bacillus strains as human probiotics: characterization, safety, microbiome, and probiotic carrier. Food Sci Biotechnol. 2019;28(5):1297-1305.
14. Kotowicz N, Bhardwaj RK, Ferreira WT, et al. Safety and probiotic evaluation of two Bacillus strains producing antioxidant compounds. Benef Microbes.2019;10(7):759-771.
15. Burtscher J, Etter D, Biggel M, et al. Further Insights into the Toxicity of Bacillus cytotoxicus Based on Toxin Gene Profiling and Vero Cell Cytotoxicity Assays. Toxins (Basel). 2021;13(4):234.
16. Castañeda-García A, Blázquez J, Rodríguez-Rojas A. Molecular Mechanisms and Clinical Impact of Acquired and Intrinsic Fosfomycin Resistance. Antibiotics (Basel). 2013;2(2):217-236.
17. Piddock LJ. Multidrug-resistance efflux pumps - not just for resistance. Nat Rev Microbiol. 2006;4(8):629-636.
18. Hooper DC, Jacoby GA. Mechanisms of drug resistance: quinolone resistance. Ann N Y Acad Sci. 2015;1354(1):12-31.
19. Nies DH. Efflux-mediated heavy metal resistance in prokaryotes. FEMS Microbiol Rev. 2003;27(2-3):313-339.
20. Rietkötter E, Hoyer D, Mascher T. Bacitracin sensing in Bacillus subtilis. Mol Microbiol. 2008;68(3):768-785.
21. Wolf D, Kalamorz F, Wecke T, et al. In-depth profiling of the LiaR response of Bacillus subtilis. J Bacteriol. 2010;192(18):4680-4693.
22. Kapse NG, Engineer AS, Diwan AD, et al. Genome profiling for health promoting and disease preventing traits unraveled probiotic potential of Bacillus clausii B106. Microbiology and Biotechnology Letters. 2018;46(4):334-345.
23. Granato D, Perotti F, Masserey I, et al. Cell surface-associated lipoteichoic acid acts as an adhesion factor for attachment of Lactobacillus johnsonii La1 to human enterocyte-like Caco-2 cells. Appl Environ Microbiol. 1999;65(3):1071-1077.
24. Kunst F, Ogasawara N, Moszer I, et al. The complete genome sequence of the gram-positive bacterium Bacillus subtilis. Nature. 1997;390(6657):249-256.
25. Ault-Riché D, Fraley CD, Tzeng CM, Kornberg A. Novel assay reveals multiple pathways regulating stress-induced accumulations of inorganic polyphosphate in Escherichia coli. J Bacteriol. 1998;180(7):1841-1847.
26. Bobay LM, Touchon M, Rocha EP. Pervasive domestication of defective prophages by bacteria. Proc Natl Acad Sci U S A. 2014;111(33):12127-12132.
27. Wang X, Kim Y, Ma Q, et al. Cryptic prophages help bacteria cope with adverse environments. Nat Commun. 2010;1:147.
28. From C, Pukall R, Schumann P, et al. Toxin-producing ability among Bacillus spp. outside the Bacillus cereus group. Appl Environ Microbiol.2005;71(3):1178-1183.